Novo Nordisk vs. Eli Lilly: Q2 prints, valuations and the GLP-1 race
Investing.com reports Q2 results for Novo Nordisk (NVO) and Eli Lilly (LLY). Lilly posted $22.97B revenue (+48% YoY) and raised FY guidance to $85–87B, while Novo reported $12.1B revenue and a 21.9% EPS beat, also raising guidance. The article cites GLP-1 drug performance, including Lilly’s Mounjaro/Zepbound and Novo’s oral Wegovy (5M+ U.S. prescriptions), plus valuation comparisons.
How this was made
The 30-second read
Why it matters
For traders, the actionable elements are the same-day earnings and guidance updates plus specific pipeline efficacy datapoints (retatrutide Phase 3, oral Wegovy prescription milestone) and the stated competitive/pricing and litigation risks.
Market read
Same-day Q2 prints and guidance raises for both NVO and LLY, plus pipeline efficacy and oral-launch traction, are likely to drive near-term positioning in GLP-1 leaders.
What to watch
Courtroom/advertising litigation and pricing-policy shifts could matter as much as efficacy, and the article flags injectable revenue pressure and trial/patent-exclusivity headwinds for NVO.
Background
The article frames the GLP-1 obesity race as a contest between Lilly’s injectable leadership and Novo’s oral Wegovy push, with both companies reporting Q2 results the same morning.
Ticker impact
Novo Nordisk reported Q2 results with a 21.9% EPS beat and raised FY guidance, plus oral Wegovy reaching 5M+ U.S. prescriptions.
Supportive for NVO on earnings-day momentum, but upside may be capped if investors discount oral growth versus competitive injectable demand.
The article provides multiple same-day fundamentals (EPS beat, guidance raise, oral prescription milestone) but also flags specific negatives (injectable revenue decline, trial failure, exclusivity losses).
Eli Lilly posted Q2 revenue of $22.97B, raised FY guidance to $85–87B, and highlighted positive Phase 3 data for retatrutide with 22.6% weight loss.
Likely continued bid versus peers given guidance raise and Phase 3 headline efficacy, despite the Q2 EPS miss.
The text includes concrete earnings/guidance numbers and a specific Phase 3 efficacy datapoint plus early access, which are direct valuation drivers.
Market effects
Reinforces GLP-1 competitive dynamics between injectable dominance (Lilly) and oral format leadership (Novo), potentially shifting investor focus to next-gen oral and triple-agonist timelines.
Medicare U.S. access framing (20M eligible) is likely to keep U.S. obesity demand expectations elevated for both names.
Oral and next-gen efficacy headlines can influence global GLP-1 pricing and formulary expectations beyond the U.S.
Counterpoint
Valuation and expectations may be doing the heavy lifting, especially for LLY, where the article notes premium multiples and rising leverage risk.
Key entities
- companyNovo Nordisk
Reported Q2 EPS beat, raised FY guidance, and cited oral Wegovy oral pill prescription momentum; also faced injectable revenue pressure and pipeline setbacks.
- companyEli Lilly
Reported Q2 revenue and raised FY guidance; highlighted positive retatrutide Phase 3 efficacy and early access, while noting an EPS miss tied to R&D charges.
- drugWegovy
Novo’s GLP-1 obesity therapy, including an oral formulation milestone cited as 5M+ U.S. prescriptions.
- drugZepbound
Lilly’s injectable tirzepatide obesity therapy, referenced as having higher U.S. weekly prescription volume than Wegovy.
- drugRetatrutide
Lilly’s triple-hormone agonist, cited with positive Phase 3 data and a planned FDA filing timeline.
